Derek Hicks Receives Stock Award at Intellia Therapeutics Inc (NTLA) — SEC Form 4, Jan 05, 2022

SEC Form 4 · No Market Transaction

Stock Award

Compensation grant — no market purchase or sale.

Reporting Owner

Derek Hicks

EVP

TXN 2022-01-03 · FILED 2022-01-05

Equity Position 19.1K sh 0 → 19,118

Filing Lag 2 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Intellia Therapeutics Inc

NTLA CIK 0001652130

Reporting Owner

Name	Relationship
Derek Hicks CIK 0001901282	EVP

Derek Hicks at Intellia Therapeutics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) —

More from this insider at Intellia Therapeutics Inc

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common StockF1	2022-01-03	A - Award/Grant	19,118 A	$0.00	—	19,118	Direct

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Stock option (right to buy)F2	$118.99	2022-01-03	A - Award/Grant	25,000 A	$0.00	2032-01-02	25,000 Common Stock	Direct

Footnotes (2)

F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Show more
F2: This option was granted on January 3, 2022 with respect to 25,000 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 25% vesting on December 20, 2022 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter. Show more

Institutional Holders

Largest by reported value

5%+ Holders · 13D/G 5 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Intellia Therapeutics Inc

GET /v1/forms/4/0001209191-22-001651 API docs